This is the first study to delineate the role of the PLAU by integrated publically available transcriptomic, proteomics, and clinical data to 1) further elucidate the mechanisms underlying PLAU-related PDAC growth and progression, 2) use this data to undertake analyses of prognostic outcomes (overall survival) and assessment of relationship with clinical attributes, 3) identify the most ‘at risk’ group based on PLAU expression and4) preclinically assess selective uPA inhibition on pancreatic cancer growth and metastasis. The gene discussed is PLAU; the disease is familial pancreatic carcinoma.